BACKGROUND AND PURPOSE: This study aimed to develop a validated survival score for elderly patients with metastatic spinal cord compression (MSCC). PATIENTS AND METHODS: In all, 1,128 patients were randomly assigned to the test (n = 564) or validation group (n = 564). In the test group, ten pretreatment factors (age, gender, performance status, primary tumor, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time to developing motor deficits) plus the radiation regimen were retrospectively evaluated. Factors significantly associated with survival on multivariate analysis were included in the survival score. The score for each factor was determined by dividing the 6-month survival rate (%) by 10. The prognostic score represented the sum of the scores for each factor. RESULTS: In the multivariate analysis of the test group, age, performance status, primary tumor type, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, and time to developing motor deficits were significantly associated with survival. Total scores ranged from 25 to 57 points. In the test group, 6-month survival rates were 11 % for 25-39 points, 56 % for 40-48 points, and 97 % for 49-57 points (p < 0.001). In the validation group, 6-month survival rates were 10, 53, and 94 %, respectively (p < 0.001). CONCLUSION: Based on the survival scores of the test group, three prognostic groups were identified. The survival rates of the validation group were similar to the test group. This score appears reproducible and can help select the appropriate treatment for elderly patients with MSCC.
RCT Entities:
BACKGROUND AND PURPOSE: This study aimed to develop a validated survival score for elderly patients with metastatic spinal cord compression (MSCC). PATIENTS AND METHODS: In all, 1,128 patients were randomly assigned to the test (n = 564) or validation group (n = 564). In the test group, ten pretreatment factors (age, gender, performance status, primary tumor, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time to developing motor deficits) plus the radiation regimen were retrospectively evaluated. Factors significantly associated with survival on multivariate analysis were included in the survival score. The score for each factor was determined by dividing the 6-month survival rate (%) by 10. The prognostic score represented the sum of the scores for each factor. RESULTS: In the multivariate analysis of the test group, age, performance status, primary tumor type, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, and time to developing motor deficits were significantly associated with survival. Total scores ranged from 25 to 57 points. In the test group, 6-month survival rates were 11 % for 25-39 points, 56 % for 40-48 points, and 97 % for 49-57 points (p < 0.001). In the validation group, 6-month survival rates were 10, 53, and 94 %, respectively (p < 0.001). CONCLUSION: Based on the survival scores of the test group, three prognostic groups were identified. The survival rates of the validation group were similar to the test group. This score appears reproducible and can help select the appropriate treatment for elderly patients with MSCC.
Authors: Dirk Rades; Lukas J A Stalpers; Theo Veninga; Rainer Schulte; Peter J Hoskin; Nermina Obralic; Amira Bajrovic; Volker Rudat; Rudolf Schwarz; Maarten C Hulshof; Philip Poortmans; Steven E Schild Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: D Rades; S Douglas; T Veninga; A Bajrovic; L J A Stalpers; P J Hoskin; V Rudat; S E Schild Journal: Strahlenther Onkol Date: 2012-04-25 Impact factor: 3.621
Authors: D Rades; S G Hakim; A Bajrovic; J H Karstens; T Veninga; V Rudat; S E Schild Journal: Strahlenther Onkol Date: 2012-08-19 Impact factor: 3.621
Authors: M N Duma; T Schuster; N Aswathanarayana; L-S Fromm; M Molls; H Geinitz; S Kampfer Journal: Strahlenther Onkol Date: 2013-10-10 Impact factor: 3.621
Authors: Tilman Bostel; Robert Förster; Ingmar Schlampp; Tanja Sprave; Sati Akbaba; Daniel Wollschläger; Jürgen Debus; Arnulf Mayer; Heinz Schmidberger; Harald Rief; Nils Henrik Nicolay Journal: Strahlenther Onkol Date: 2019-06-25 Impact factor: 3.621
Authors: Alexander Rühle; Verlaine Ange Nya Yompang; Simon K B Spohn; Raluca Stoian; Constantinos Zamboglou; Eleni Gkika; Anca-Ligia Grosu; Nils H Nicolay; Tanja Sprave Journal: Radiat Oncol Date: 2022-09-07 Impact factor: 4.309
Authors: Dirk Rades; Antonio J Conde; Raquel Garcia; Jon Cacicedo; Barbara Segedin; Ana Perpar; Steven E Schild Journal: Radiat Oncol Date: 2015-08-19 Impact factor: 3.481
Authors: Dirk Rades; Antonio Jose Conde-Moreno; Jon Cacicedo; Theo Veninga; Niklas Gebauer; Tobias Bartscht; Steven E Schild Journal: BMC Cancer Date: 2016-04-25 Impact factor: 4.430